Effective immediately, UPMC members will be charged the $350 administration fee that Medicare has set as the basis for providers. You can pay in cash or credit card. Checks will not be accepted. Like any other medical treatment, you may be subject to a copay or deductible if your insurance requires it. We will continue to make every effort to serve our uninsured population with no cost to the patient.
If you are uninsured, there will be a $350 administration fee due at the time of the appointment. We accept most major credit cards and cash payment.
There is limited data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. mAb treatment therapy should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus. There is no available data on the presence of casirivimab and/or imdevimab in human milk or animal milk, the effects on the breastfed infant, or the effects of the drug on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for mAb therapy and any potential adverse effects on the breastfed child from mAb therapy or from the underlying maternal condition.
We do not require proof of your positive test. Just bring your photo ID and insurance card with you to your appointment.
Monoclonal antibody (mAb) therapy, also called monoclonal antibody infusion treatment, is a way of treating COVID-19. The goal of this therapy is to help prevent hospitalizations, reduce viral loads and lessen symptom severity. This type of therapy relies on monoclonal antibodies. These are antibodies that are similar to the ones your body would naturally make in response to infection. They give the immune system a leg up until it can mount its own response.